Author/s:
Hapgood, G;Latimer, M;Lee, ST;Kuss, B;Lade, S;Tobin, JWD;Purtill, D;Campbell, BA;Prince, HM;Hawkes, EA;Shortt, J;Radeski, D

Title:
Diagnosis, management and follow up of peripheral T-cell lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance

Date:
2022-10-01

Citation:
Hapgood, G., Latimer, M., Lee, S. T., Kuss, B., Lade, S., Tobin, J. W. D., Purtill, D., Campbell, B. A., Prince, H. M., Hawkes, E. A., Shortt, J. & Radeski, D. (2022). Diagnosis, management and follow up of peripheral T-cell lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance. Internal Medicine Journal, 52 (10), pp.1806-1817. https://doi.org/10.1111/imj.15595.

Hapgood Greg (Orcid ID: 0000-0002-7980-8496)
Lee Sze Ting (Orcid ID: 0000-0001-8641-456X)
Hawkes Eliza (Orcid ID: 0000-0002-0376-2559)

Diagnosis, management and follow up of peripheral T cell lymphomas: A Consensus Practice Statement from the Australasian Lymphoma Alliance

Hapgood.G[1,2], Latimer. M[3], Lee. S.T[4,5], Kuss. B[6,7], Lade. S[8], Tobin. J.W.D[9,10], Purtill. D[11,12], Campbell. B.A[5,8], Prince. H.M[5,8], Hawkes. E.A[4,5], Shortt. J[13,14], Radeski. D[11,15]

Corresponding Author: Greg Hapgood

Dept Haematology, Princess Alexandra Hospital, 199 Ipswich Rd, Woolloongabba QLD 4102, Australia

Email: Greg.Hapgood@health.qld.gov.au

Author Details & Affiliations

Greg Hapgood, Haematologist,
[1] Princess Alexandra Hospital, Brisbane, Australia
[2]University of Queensland, Brisbane, Australia
Maya Latimer, Haematologist,
[3] The Canberra Hospital, Canberra, Australia
Sze Ting Lee, Nuclear Medicine Physician
[4]Olivia Newton John Cancer Research Institute, Austin Health, Melbourne, Australia
[5]University of Melbourne, Melbourne, Victoria, Australia
Bryone Kuss, Haematologist
[6]Flinders University, Bedford Park, Australia
[7]Flinders Medical Centre, Bedford Park, Australia
Stephen Lade, Anatomical Pathologist
[8]Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Joshua W.D. Tobin, Haematology advanced trainee
[9]Mater Health, South Brisbane, Australia
[10]Mater Research Institute, University of Queensland, Brisbane, Australia
Duncan Purtill, Haematologist,
[11]University of Western Australia, Perth, Australia
[12]Fiona Stanley Hospital, Perth, Australia
Belinda A. Campbell, Radiation Oncologist
[5]University of Melbourne, Melbourne, Victoria, Australia
[8]Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
H.Miles Prince, Haematologist
[5]University of Melbourne, Melbourne, Victoria, Australia
[8]Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Eliza A Hawkes, Medical Oncologist
[4]Olivia Newton John Cancer Research Institute, Austin Health, Melbourne, Australia
[5]University of Melbourne, Melbourne, Victoria, Australia
[13]Monash University, Clayton, Australia
Jake Shortt, Haematologist
[13]Monash University, Clayton, Australia
[14]Monash Health, Clayton, Australia
Dejan Radeski, Haematologist
[15]Sir Charles Gairdner Hospital, Nedlands, Australia.

Author Contributions

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/imj.15595

GH: coordinated the project, drafted, revised, critically reviewed and edited the work.

DR: drafted, revised and critically reviewed the work.

ML, STL, BK, SL, JT, DP, BC, MP, EH, JS: drafted and reviewed the work.

All authors contributed to the design of the work, approved the final version and are accountable for all aspects of the work

Conflict of Interest

JT: Honorarium – Roche.

MP: Advisory boards – Takeda, BMS-Celgene, Allergan. Research Grant – Allergan.

EH: Advisory board - Merck Sharpe & Dome, Gilead, Roche, Antigene, Astra Zeneca, Bristol Myers Squibb, Janssen. Research Grants - Bristol Myers Squibb, Merck KgA, Astra Zeneca and Roche, Speaker's bureau - Janssen, Roche.

JS: Advisory board – Astellas, BMS/Celgene. Research funding – Amgen, Astex, BMS/Celgene. Speaker's bureau – Takeda.

GH: Advisory board – Takeda.

Word count

Abstract- 170
Main Document: 3802

ABSTRACT

Peripheral T-cell lymphomas (PTCLs) represent a heterogeneous disease group accounting for 10% of non-Hodgkin lymphomas. PTCL patients have typically poorer outcomes compared to aggressive B-cell lymphomas. However, such outcomes are heavily dependent upon subtype. Although anthracycline-based regimens such as cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) remain the standard first-line treatment for most aggressive PTCLs, there are important variations including incorporation of novel agents, use of radiotherapy and judicious consideration of stem cell transplantation. Relapsed or refractory disease represents a significant area of unmet need where chemotherapy intensification has limited efficacy and novel agents such as brentuximab vedotin and pralatrexate provide additional opportunities for attainment of remission and potential

stem cell transplant. In the future, pre-therapy prognostic biomarkers including genomic characterisation, may aid in risk stratification and help guide initial patient management to improve survival. There is an urgent need to better understand the pathogenesis of PTCLs to facilitate novel drug combinatorial approaches to improve survival. This position statement represents an evidence-based synthesis of the literature for application in Australian and New Zealand practice.

KEYWORDS

Peripheral T-cell Lymphoma, PTCL, AITL, ALCL, chemotherapy.

INTRODUCTION

Peripheral T-cell lymphomas (PTCL) are a heterogeneous category of mature, typically nodal lymphomas arising from post-thymic (*i.e.* "peripheral") T-cells[1] with typically aggressive clinical courses. This position statement addresses the management of the major nodal and extranodal PTCLs.

METHODOLOGY

This Consensus Practice Statement was undertaken by a panel of lymphoma experts with particular interest in PTCL under the auspices of the Australasian Lymphoma Alliance (ALA) in accordance with the ALA Consensus Practice Statement development policy. The relevant literature was reviewed by the expert authors. Levels of evidence and grades of recommendation have been applied using the system shown in Tables 1 and 2. Statements without grading were considered justified standard clinical practice by the experts and the ALA members. Feedback from key stakeholders was also sought.

EPIDEMIOLOGY/CLINICAL PRESENTATION

PTCLs represent 5-15% of non-Hodgkin lymphomas[1]. Nodal subtypes predominate and frequently present with B-symptoms, advanced stage and extranodal involvement. The most frequent subtype, PTCL not otherwise specified (PTCL NOS), is a heterogeneous category of nodal and extranodal mature T-cell lymphomas that do not correspond to any of the specifically defined entities of mature T cell lymphoma in the current classification[1]. It is a diagnosis of exclusion, represents 20-40% of all PTCLs with a median age of 60 years[2]. Angioimmunoblastic T cell lymphoma (AITL) represents approximately 20% of PTCLs with a median age of 60-65 years[5] and is the most common subtype of PTCL of follicular T helper origin. It is often associated with a subacute systemic prodrome that may mimic infection or autoimmune disease and lead to a delayed or misdiagnosis. Anaplastic lymphoma kinase (ALK)-

positive anaplastic large cell lymphoma (ALCL) is more commonly seen in young adults (median age 30 years), whereas ALK-negative ALCL occurs in older adults (median age 55 years)[3,4]. Extranodal subtypes include enteropathy-associated T-cell lymphoma (EATL) and extranodal NK/T-cell lymphoma (NKTCL). EATL is usually associated with coeliac disease. Patients are frequently in their 60s and present with pain, perforation or obstruction from bowel involvement. NKTCL is strongly associated with Epstein Barr virus (EBV) infection and most commonly seen in Asia with a predilection for the nasal/sinus region.

DIAGNOSIS

Diagnosis of PTCLs requires correlation of clinical, histological, immunophenotypic, cytogenetic and molecular information. Correct subclassification is important to rationalise access to novel agents and clinical trial enrolment. Classification is challenging with consensus ranging from 67-95% among expert haematopathologists[2,6]. Surgical biopsy is recommended for adequate tissue for assessment. Immunohistochemistry (IHC) is usually more extensive than for other lymphomas. Typical work up includes pan T-cell antigens (CD2, CD3, CD5, CD7), T-cell subsets (CD4, CD8), T follicular helper cell antigens (CD10, PD1), follicular dendritic antigens (CD21, CD23, CD35), B-cell antigens (CD20), EBV, CD30 and ALK-1. Molecular testing using polymerase chain reaction (PCR) assessment of clonal T-cell receptor (TCR) rearrangements has traditionally been used, but such assays lack both sensitivity and specificity. Demonstration of TCR clonality is not synonymous with malignancy as this may be observed in reactive conditions.

A variety of fluorescence *in situ* hybridisation probes are used for PTCLs, most commonly to provide prognostic information in ALK-negative ALCL. Two mutually exclusive and clinically significant rearrangements have been described in this tumour involving the *DUSP22-IRF4* locus and the *TP53* homolog *TP63*, identifying favourable and adverse prognostic groups, respectively[7]. The so-called triple negative group (negative for *ALK*, *DUSP22* and *TP63* rearrangements) may also prove to be biologically mixed[8].

Next generation sequencing holds promise to improve the diagnosis, subclassification, and prognostication of PTCLs. The detection of mutations for sequence variants such as *TET2/DNMT3A/IDH2* is becoming more readily available in the routine work up of suspected PTCL[9-12].

Recommendations

-Surgical biopsy and multidisciplinary review including an expert lymphoma pathologist are recommended to ensure the correct PTCL subclassification for treatment planning, rationalising access to novel agents and clinical trial enrolment.

STAGING

Identification of B-symptoms, physical examination and laboratory tests including full blood examination, hepatic and renal testing, lactate dehydrogenase (LDH) and screening for HIV, Hepatitis B and C are required. Almost all PTCLs are avid with ^{18}F-fluorodeoxyglucose positron emission tomography (PET)[13,14]. All patients should be preferably staged with PET/ computed tomography (CT), if available, at diagnosis[15]. Bone marrow biopsy is required for staging purposes, to assess haemopoiesis and the presence of haemophagocytic syndrome. Lumbar puncture and magnetic resonance imaging (MRI) are required if central nervous system (CNS) involvement is suspected. Staging is performed according to the Ann Arbor classification[15]. MRI and endoscopic evaluation are important in NKTCL for staging and radiotherapy (RT) planning.

Recommendation

-All patients should be preferably staged with PET/CT, if available, and bone marrow biopsy.

PROGNOSTIC FACTORS

The prognosis of PTCL is determined by the specific histological subtype. The International Prognostic Index (IPI) has been validated in PTCLs[16] and is the most widely used tool. Several alternative PTCL-specific tools have been developed, including the prognostic index for T cell lymphoma (PIT) [17], the modified PIT[18], a PTCL-NOS specific score [19], age-adjusted IPI [20] and the Glasgow prognostic score [21]. Few of these prognostic scores have been adopted in routine practice. For practical purposes, the IPI remains a recommended tool.

Recommendation

- The IPI remains useful across PTCL subtypes.

MANAGEMENT

First-line treatment: PTCL NOS, AITL, ALCL

First-line treatment should be tailored to a patient's age, fitness and co-morbidities. Given the rarity of PTCLs and poorer outcomes, clinical trial participation should be considered the standard of care where available. Our recommended treatment algorithm is shown in Figure 1. The initial goal is to achieve long-term remission or cure. Historically, first-line therapy for nodal PTCLs has been identical across histological subtypes. Most evidence comes from retrospective PTCL studies or subgroup

analyses[22] of prospective trials of aggressive B- and T-cell lymphomas with inadequate statistical power to determine T-cell specific outcomes[23].

CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)-based chemotherapy evolved as standard of care for PTCLs based on extrapolation of treatment paradigms for aggressive B-cell lymphomas[23]. The International PTCL project reported 5-year OS rates of 32% for PTCL NOS, 33% for AITL, 70% for ALK+ ALCL and 49% for ALK- ALCL in patients treated primarily with CHOP based regimens[2]. While outcomes were comparable to non-anthracycline based regimens, this was a retrospective analysis and treatment decisions are likely to have been influenced by patient factors. Reducing the time interval from 3 to 2 weeks (CHOP-21 vs CHOP-14) or administering 8 instead of 6 cycles of chemotherapy did not improve event-free survival (EFS) or OS in elderly patients[22].

The main regimen purported to offer benefit over CHOP is CHOP plus etoposide (CHOEP) but is yet to be tested in a prospective trial. In an initial retrospective analysis of CHOEP in selected PTCL patients (<60 years, normal LDH), the addition of etoposide improved EFS but not OS[22]. Similarly, the Swedish registry demonstrated improved PFS but not OS for patients <60 years[24]. Conversely, outcomes were not improved in a meta-analysis[25] or a national registry analysis[26]. The use of dose-escalated CHOEP (High-CHOEP) or a mega-dose (MegaCHOEP) variant which incorporated stem cell rescue[22] or hyper-CVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine)[27,28] also demonstrated no improved OS over CHOP.

Other chemotherapy regimens have not proven superior to CHOP. Randomised controlled trials (RCT) comparing GEM-P (gemcitabine, cisplatin, methylprednisolone) or VIP (etoposide, ifosfamide, cisplatin)/ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) to CHOP did not demonstrate improved CR rates (CHOP 62% vs GEM-P 46%; *P*=0.16) or 2-year EFS (CHOP 45% vs VIP/ABVD 41%; *P* = 0.7)[29,30].

Brentuximab vedotin (BV) is an antibody drug conjugate consisting of an anti-CD30 monoclonal antibody conjugated to a microtubule inhibitor, monomethyl auristatin E. BV-CHP (cyclophosphamide, doxorubicin, prednisone) demonstrated superior progression-free survival (PFS) compared to CHOP in CD30+ (defined as ≥10% of cells) PTCLs[31,32]. Approximately 70% of patients had ALCL (ALK+ IPI 2-5, ALK- ALCL) and an improved PFS was reported for this secondary endpoint for receiving BV-CHP. Importantly, the study was not powered to assess PTCL subgroups such as PTCL-NOS or AITL. This is the first RCT to demonstrate improved PFS compared to CHOP in PTCLs.

Recent studies investigating the addition of novel agents (alemtuzumab, bevacizumab, romidepsin) to CHOP have not demonstrated superiority over CHOP alone and were associated with increased toxicity [33-38].

Recommendation

- CHOP every 21 days for 6 cycles is the recommended first-line treatment (II, A).

- Consideration may be given for CHOEP for patients aged <60 years with a normal LDH (III-2, C).

- Dose intensification beyond CHO(E)P is not recommended outside investigational studies (III-2, C).

- For all patients with ALCL, BV-CHP for 6 cycles is recommended, if funded and available (II, B).

- The benefit of the addition BV to chemotherapy in other CD30 positive (defined as ≥10% of cells) PTCL subtypes is less clear due to small patient numbers. There is no evidence to support a role of BV in AITL. There is no recognized relationship between CD30 expression (≥10% of cells) and response to BV-CHP. Based on current evidence, outside the setting of a clinical trial, BV is not routinely recommended for non-ALCL subtypes but can be considered on a case-by-case basis (II, C). Access to government-funded novel agents can vary within Australia (PBS) and New Zealand (Pharmac).

Role of RT in limited-stage PTCL

Following systemic therapy, consolidation RT is recommended for limited-stage (stage I/II) PTCL treated with curative-intent. Although randomised evidence is lacking, retrospective series report clinically significant improvements in disease-specific survival, PFS and OS with consolidative RT in limited stage PTCL-NOS[39-43]. A recently published analysis using the National Cancer Database (NCDB) of 3670 patients with early stage PTCL-NOS and ALK negative ALCL reported an OS benefit favouring the addition of consolidation RT (HR 0.69 (95% CI:0.58-0.84; p<0.01) on multivariate analysis[41]. Further, data analysed from the Surveillance, Epidemiology, and End Results (SEER) database revealed an improvement in 5-year OS from 35% to 59% with the addition of RT in patients with limited-stage PTCL-NOS (HR 0.527, 95% CI: 0.427–0.651, P<0.001)[43]. There is no evidence for an adapted PET-guided approach for the omission of RT in limited stage PTCL.

In RT planning, expert opinion favours the use of involved node radiotherapy (INRT)/involved site radiotherapy (ISRT) for limited stage PTCLs, to reduce the risk of RT-induced toxicities [44-46]. Principles

of INRT/ISRT are described by the International Lymphoma Radiation Oncology Group[45,47,48]. Pre-chemotherapy PET/CT imaging is strongly recommended for accurate target delineation and optimally performed in the RT treatment position[47]. Limited data exists for the dose-responsiveness of PTCL. Based on expert opinion, recommended doses for consolidation RT are 30-40Gy, delivered in conventional fraction sizes of 1.8-2Gy[19,45,49]. Higher doses of 40-50Gy may be considered for sites achieving partial response to frontline chemotherapy[19,45].

Recommendation:

-Consolidative RT is recommended for limited-stage PTCLs (III-2, C).

-There is no evidence that chemotherapy can be safely abbreviated in limited stage PTCL if RT is used (III-2, C).

Role of autologous transplantation in first remission

Consolidation with high-dose chemotherapy (HDT)/autologous stem cell transplantation (ASCT) aims to reduce the high relapse rate following first complete remission (CR1) with CHOP-based chemotherapy. Prospective data reporting outcomes with CHOP represent the most appropriate 'benchmark' to compare HDT/ASCT studies. Recent prospective studies have demonstrated 3-year PFS on 28-44% for patients receiving CHOP chemotherapy[50,51].

Two phase II studies examined the role of consolidative HDT/ASCT. The Nordic Lymphoma Group (NLG-T-01) reported 5-year PFS of 44% and OS of 55% with CHOEP + BEAM or BEAC HDT/ASCT[52]. A German study used CHOP21 + dexaBEAM then total body irradiation/cyclophosphamide or BEAM HDT/ASCT and reported a 5-year PFS of 36% and OS of 48% [53]. Importantly, 25-30% of patients failed to proceed to ASCT in these studies, mostly due to refractory or progressive disease. Patients with ALK+ ALCL were excluded from both studies on the basis of favourable outcomes with chemotherapy alone[2,22]. Other studies have not clearly demonstrated a survival benefit, with physician bias limiting the interpretation of results [54,55].

Outcomes following consolidative HDT/ASCT purport to be superior to chemotherapy alone[2,5,39,56]. Despite the lack of an RCT, guidelines recommend considering HDT/ASCT in CR1 for PTCLs other than standard-risk ALK positive ALCL[57-59]. The major arguments against consolidative HDT/ASCT are the absence of RCT data and possible selection biases limiting non-randomised studies. An RCT compared consolidative ASCT to allogeneic SCT (AlloSCT) and demonstrated similar EFS with more deaths from relapse in the ASCT group and more deaths from toxicity in the AlloSCT group [60]. This data confirms a graft-versus-lymphoma effect in PTCLs.

Recommendation:

-Consolidative ASCT could be considered for AITL, PTCL NOS and ALK negative ALCL(III-3, C).

-Consolidative ASCT is not recommended for standard-risk ALK+ ALCL (III-3, C).

-If considering consolidative transplantation, ASCT is recommended over alloSCT due to the high treatment-related mortality and similar outcomes (II,C).

RELAPSED/REFRACTORY PTCL TREATMENT

Patients with relapsed/refractory (RR) PTCLs have a poor prognosis with a median OS of approximately 6 months and 3-year overall survival of approximately 20% [61]. Moreover, the pathology and biology of PTCL is complex and may evolve over time. Our recommended treatment algorithm is shown in Figure 2.

Recommendation

- **Repeat biopsy of relapsed/refractory disease is highly recommended prior to initiation of salvage therapy (IV,A).**
- **We encourage presentation of all cases to local and national multidisciplinary team meetings and participation in clinical trials (IV,A).**

ALCL

The use of BV in RR ALCL is supported by a phase II trial where the 5-year OS was 60% [62]. No survival differences were detected between patients with ALK-positive and ALK-negative status. Patients in CR who received ASCT experienced improved 5-year PFS but no difference in OS compared to eligible patients who were not transplanted. The benefit of consolidative ASCT for such patients is unclear and should be performed at the clinician's discretion. Retreatment with BV can be effective in patients who have previously obtained a CR or partial remission to BV [63]. The *t*(2;5) translocation leads to the formation of a novel *NPM-ALK* chimeric protein which has constitutive tyrosine kinase activity[64]. Crizotinib is an oral ALK inhibitor that demonstrated activity in heavily pre-treated ALK positive ALCL patients with an ORR was 90% (10/11) and 2 y OS of 72% and PFS of 63%[65].

Recommendation

- **BV is recommended as second line therapy in ALCL irrespective of ALK status (III-3,A).**
- **ALK inhibitors may be used in the relapsed/refractory setting in ALK positive ALCL after BV (III-3,C).**

PTCL-NOS and AITL

Optimal therapy for RR PTCL/AITL remains to be defined and is presently based upon the goal of care, expected toxicities and patient comorbidities. There is consensus that ASCT should be attempted in eligible patients. The International PTCL Project identified that transplant-eligible patients who proceeded to ASCT had improved 3-year survival after relapse compared to those who did not (48% versus 27%)[61]. In this analysis, those ineligible for ASCT had a 3-year survival of 7%.

Transplant-eligible patients

In patients proceeding to ASCT, salvage chemotherapy regimens have been investigated with no clear superiority of any regimen. The only RCT in this setting was a subgroup analysis of the LY.12 trial comparing GDP (gemcitabine, dexamethasone, cisplatin) to DHAP (dexamethasone, cytarabine, cisplatin) which did not identify significant differences in response rate, ASCT realisation rate, EFS or OS[66].

Transplantation – Autologous versus Allogeneic

The CIBMTR reported outcomes of patients who underwent ASCT or AlloSCT for PTCL beyond CR1 [67]. Three-year OS was 53% for ASCT and 46% for alloSCT. Although AlloSCT recipients had more poor prognostic features, on multivariate analysis, AlloSCT was associated with higher non-relapse and overall mortality, without an associated reduction in relapse risk.

Transplant-ineligible patients

There is increasing evidence that outcomes may be improved by the earlier use of novel agents. When used in first retreatment, analysis of the COMPLETE data identified a PFS benefit and the Columbia data demonstrated an OS benefit for patients receiving a novel agent over chemotherapy [68,69]. In transplant-ineligible patients or patients who have failed one line of salvage chemotherapy, we suggest a novel agent.

Novel agents

Pralatrexate. In the PROPEL phase II trial, pralatrexate (dihydrofolate reductase inhibitor) showed an overall response rate (ORR) of 29%, with a subset analysis suggesting improved ORR of 47% when used as second line treatment post CHOP [70,71]. Concern has been raised about its efficacy in AITL but a phase I/II trial demonstrated an ORR 45% [72]. The Columbia regimen uses pralatrexate weekly for 3 weeks in a 4-week cycle with leucovorin for mucositis prophylaxis [73]. Leucovorin prophylaxis is associated with reduced rates of mucositis with no apparent impact upon efficacy[74]. Stem cell collection and transplantation remains feasible[71].

Brentuximab vedotin. BV possess modest activity in non-ALCL CD30+ nodal PTCLs with an ORR of 41% in a phase II trial [75].

Histone deacetylase inhibitors. In a phase II study, romidepsin demonstrated an ORR of 25% including 15% CR/CR unconfirmed. There was no difference in response rate based on the number of prior lines of therapy[76].

Hypomethylating agents and 'epigenetic combinations'. AITL has a high frequency of mutations in genes regulating DNA methylation (*TET2*, *DNMT3A* and *IDH2*) that may correlate with responses to epigenetically targeted drugs such as hypomethylating agents and histone deacetylase inhibitors. However, patients without such mutations may also respond to epigenetic therapy and so the utility of mutation detection in therapeutic decisions is guarded [77]. A subset of PTCL patients may have concurrent manifestations of clonal haematopoiesis such as myelodysplastic syndromes [78]. Combination 'novel-novel' strategies are now being evaluated and hold promise including pralatrexate/romidepsin and romidepsin/azacitidine [79,80].

Cyclosporin. In a subset of patients, PTCL behaves in an indolent fashion with slow disease kinetics and a relapsing/remitting course. This is more commonly seen with AITL where modulating T-cell activation with cyclosporin has been hypothesized to be able to control disease. A retrospective study in AITL patients identified an ORR of 67% [81].

Role of Radiotherapy in relapsed/refractory disease

RT may be considered for local disease control. Expert opinion recommends RT doses of 30-36Gy for sites of complete response following salvage therapy, 40-45Gy to sites of incompletely responding residual disease, and 45-55Gy to sites of chemo-refractory progressing disease [45]. For patients with localised disease who relapse and are unfit for chemotherapy, definitive RT doses of 45-55Gy may be considered for local control [45]. For patients requiring palliative-intent symptom control only, lower doses of RT are recommended: a standard hypofractionated course of 30Gy in 10 fractions is acceptable.

Recommendation

- **There is no standard of care for second line regimens and acceptable choices include combination chemotherapy or novel agents. Selection of second line therapy is dependent on intent of therapy, comorbidities and transplant eligibility (III-2,C).**
- **Novel agents should be considered in patients who are transplant eligible and have received ≥2 lines of chemotherapy or who are transplant ineligible and have received ≥1 of chemotherapy (III-2,C).**
- **Access to government-funded novel agents can vary within Australia (PBS) and New Zealand (Pharmac).**
- **In eligible chemotherapy sensitive patients who have not previously had a stem cell transplant we recommend ASCT over alloSCT (III-2,B).**
- **Eligible patients who have relapsed following ASCT should be considered for AlloSCT (III-2,C).**

EXTRANODAL NK/T CELL LYMPHOMA (NKTCL)

Newly diagnosed limited stage (stage I/II) disease.

Outcomes with CHOP chemotherapy are poor[82]. Non-anthracycline protocols have been shown in a retrospective study to improve PFS and OS but there have been no RCTs examining individual chemotherapy and radiotherapy protocols[83]. There are multiple non-anthracycline regimens available (SMILE, DDGP, DeVIC, VIPD, GELOX) with no RCT to guide treatment[84-86]. Combined modality therapy (CMT, chemo-radiotherapy) can be performed either with a concurrent or sequential approach, with no OS difference between the two strategies with non-anthracycline

containing regimens[87]. Pre-chemotherapy PET/CT, MRI and endoscopic evaluation are strongly recommended for target volume delineation pre-RT. In those unfit for CMT, RT alone (50-60Gy) is recommended.

Recommendation

- **CMT is recommended for limited stage disease. CMT with non-anthracycline containing chemotherapy can be delivered in either a sequential or concurrent approach; choice of protocol has to factor in patient fitness and treatment unit familiarity (III-2,B).**
- **For patients unfit for CMT, RT alone is acceptable (III-2,B).**

Newly diagnosed advanced extranodal NKTCL (stage III/IV disease)

The optimal treatment strategy for advanced stage NKTCL has not been defined; however, CHOP-based therapy is not recommended due to lack of efficacy. An RCT comparing 6 cycles of DDGP (dexamethasone, gemcitabine, cisplatin, pegasparaginase) versus SMILE (dexamethasone, methotrexate, ifosphamide, L-asparaginase, etoposide) demonstrated a 5-year OS benefit in favour of DDGP [88]. Caveats to interpretation of this study are that the optimal number of cycles of SMILE has not been established and asparaginase dosing differed between this RCT and early SMILE trials. A modified SMILE protocol has been developed utilizing pegasparaginase [89].

The role of consolidative ASCT in first line therapy is uncertain given the absence of high-quality evidence in patients receiving asparaginase-based protocols. The CIBMTR identified patients having an AlloSCT in first-line therapy did not have superior survival to those receiving AlloSCT in later lines of therapy [90].

Recommendation

- **Asparaginase-based therapy is considered standard of care with DDGP preferenced over SMILE (II,B).**
- **Consolidative stem cell transplantation is not recommended (III-2,B).**

Relapsed/Refractory Disease

Examples of therapies used include DDGP, SMILE, AspaMetDex (L-asparaginase, methotrexate, dexamethasone)[86,91,92]. For those refractory to asparaginase-based therapy, immune checkpoint inhibitors have shown encouraging activity in case series [93,94].

Recommendation

- **Patients who relapse following non-asparaginase based therapies should have treatment with asparaginase-based protocols and be considered for transplantation (III-2,B).**
- **For patients refractory to asparaginase-based therapies, no standard of care is established. Immune checkpoint inhibitors display promise but require further study (IV,C).**

ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA (EATL)

EATL (previously type I) is a recognised complication of coeliac disease and should be considered in refractory coeliac disease/gluten enteropathy. Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), previously known as type II EATL, occurs in patients with no clear association with coeliac disease. Surgical resection may be required if extensive disease is present or there is risk of obstruction, haemorrhage or perforation. Surgical resection may also be considered for unifocal disease. Nutritional supplementation with total parenteral nutrition is an important part of care as malnourishment contributes to treatment failure. Outcomes with CHOP are poor (median OS < 1year)[95-99]. Limited data suggests the CHOP/IVE/MTX (ifosfamide, vincristine, etoposide, methotrextate)-ASCT protocol has been associated with superior outcomes where deliverable[95].

Recommendation

- **A multidisciplinary approach with surgery, nutritional support and systemic therapy is required.**
- **CHOP, CHOEP or IVE/MTX-ASCT could be considered for front-line treatment based on age, comorbidities and performance status (III-2,C).**

PTCL RESPONSE ASSESSMENT AND FOLLOW UP

As almost all PTCLs are FDG-avid [100-103], all patients should undergo end-of-treatment assessment with PET/CT, where feasible. There is insufficient evidence for interim PET/CT and response adapted therapy; however, where available, interim PET/CT is preferred to CT to improve the detection of disease in certain sites (e.g., gastrointestinal sites, skin). Results of PET/CT imaging should be reported using the five-point Deauville score in accordance with current Lugano international

lymphoma guidelines [104]. Sites of residual metabolic activity on end-of-treatment PET/CT should be investigated further with biopsy (preferred) or serial follow-up imaging prior to further treatment decisions. Bone marrow biopsy should be repeated for patients with initial involvement. In accordance with international guidelines for other aggressive lymphomas, follow up should be performed every three months for the first two years from diagnosis, six monthly for the next three years, then annually to detect relapse and assess for treatment-related adverse events [104]. Routine surveillance imaging is not recommended.

Recommendations

-End-of-treatment PET imaging should be performed, where feasible (III-2,C).

-Patients with positive bone marrow biopsy at diagnosis should have an end-of-treatment bone marrow biopsy (III-2,C).

- For patients achieving complete remission, surveillance imaging is not recommended (III-3,C).

REFERENCES

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (Eds). WHO Classification of Tumours of Haemopoietic and Lymphoid Tissues. (Revised 4th Edition) Lyon IARC, 2017.
2. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. *J Clin Oncol.* 2008;26(**25**):4124-4130.
3. Savage K J, Harris NL, Vose JM, Ullrich F. Jaffe ES, Connors JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. *Blood.* 2008;111(**12**):5496-5504.
4. Sibon D, Fournier M, Briere J, Lamant L, Haioun C, Coiffier B, et al. Long-Term Outcome of Adults With Systemic Anaplastic Large-Cell Lymphoma Treated Within the Groupe d'Etude des Lymphomes de l'Adulte Trials. *J Clin Oncol.* 2012;30(**32**):3939-3946.
5. Federico M, Rudiger T, Bellei M, Nathwani B, N Luminari, S Coiffier B, et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. *J Clin Oncol.* 2013;31(**2**):240-246.
6. Hsi ED, Said J, Macon WR, et al. Diagnostic accuracy of a defined immunophenotypic and molecular genetic approach for peripheral T/NK-cell lymphomas. A North American PTCL study group project. *Am J Surg Path.* 2014;38(**6**):768-775.
7. Parrilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson RA, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. *Blood.* 2014;124(**9**):1473-1480.
8. Hapgood G, Ben-Neriah S, Mottok A, Lee DG, Robert K, Villa D et al. Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma. *Brit J Haematol.* 2019;186(**3**):e28-e31.
9. Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N, et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. *Blood.* 2014;123(**9**):1293-1296.
10. Sakata-Yanagimoto M, Enami T, Yoshida K, Shiraishi Y, Ishii R, Miyake Y, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. *Nat Genet.* 2014;46(**2**):171-175.
11. Palomero T, Couronné L, Khiabanian H, Kim MY, Ambesi-Impiombato A, Perez-Garcia A, et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. *Nat Genet.* 2014;46(**2**):166-170.
12. Wang C, McKeithan TW, Gong Q, Zhang W, Bouska A, Rosenwald A, et al. IDH2 R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. *Blood.* 2015;126(**15**):1741-1752.
13. Casulo C, Schoder H, Feeney J, Lim R, Maragulia J, Zelenetz AD, et al. 18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma. *Leuk Lymphoma.* 2013;54(**10**):2163-2167.
14. Khong PL, Pang CB, Liang R, Kwong YL, Au WY. Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies. *Ann Hematol.* 2008;87(**8**):613-621.
15. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. *J Clin Oncol.* 2014;32(**27**):3059-3068.
16. International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. *N Engl J Med.* 1993;329(**14**):987-994.
17. Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, et al. Peripheral T-cell

lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. *Blood.* 2004;103(**7**):2474-2479.
18. Went P, Agostinelli C, Gallamini A, Piccaluga PP, Ascani S, Sabattini E, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. *J Clin Oncol.* 2006;24(**16**):2472-2479.
19. Federico M, Bellei M, Marcheselli L, Schwartz M, Manni M, Tarantino V, et al. Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network. *Br J Haematol.* 2018;181(**6**):760-769.
20. Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P, et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. *Leukemia.* 2006;20(**9**):1533-1538.
21. Huh SJ, Oh SY, Lee S, Lee JH, Kim SH, Lee G-W, et al. The Glasgow Prognostic Score is a significant predictor of peripheral T-cell lymphoma (PTCL) treated with CHOP-based chemotherapy and comparable with PTCL prognostic scores. *Int J Haematol.* 2019;110(**4**):438-446.
22. Schmitz N, Trumper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. *Blood.* 2010;116(**18**):3418-3425.
23. Fisher R, Gaynor E, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. A phase III comparison of CHOP vs m-BACOD vs ProMACE-CytaBOM vs MACOP-B in patients with intermediate or high-grade non-Hodgkin's lymphoma: Preliminary results of SWOG-8516 (Intergroup 0067), the national high priority lymphoma study. *Proc Am Soc Clin Oncol.* 1992;(**11**):315 (abstract 1067).
24. Ellin F, Landström J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. *Blood.* 2014;124(**10**):1570-1577.
25. Deng S, Lin S, Shen J, Zeng Y. Comparison of CHOP vs CHOPE for treatment of peripheral T-cell lymphoma: a meta-analysis. *OncoTargets Ther.* 2019;(**12**):2335-2342.
26. Kim YA, Byun JM, Park K, Bae GH, Lee D, Kim DS, et al. Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma. *Blood Adv.* 2017;1(**24**):2138-2146.
27. Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, et al. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. *Annals Oncol.* 2014;25(**11**):2211-2217.
28. Hapgood G, Stone JM, Zannino D, George A, Marlton P, Prince HM, et al. A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma. *Leuk Lymphoma.* 2019;60(**4**):904-911.
29. Simon A, Peoch M, Casassus P, Deconinck E, Colombat P, Desablens B, et al. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. *Br J Haematol.* 2010;151(**2**):159-166.
30. Gleeson M, Peckitt C, To YM, Edwards L, Oates J, Wotherspoon A, et al. CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. *Lancet Haematol.* 2018;5(**5**):e190-e200.
31. Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. *Lancet.* 2019;393(**10168**):229-240.
32. Horwitz SM, O'Connor OA, Pro B, Illidge T, Iyer SP, Advani R, et al. The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+ CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma.

Blood. 2020;136:3-5.
33. Kim JG, Sohn SK, Chae YS, Cho YY, Yang DH, Lee JJ, et al. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. *Cancer Chemother Pharmacol.* 2007;60(**1**):129-134.
34. Kluin-Nelemans HC, van Marwijk Kooy M, Lugtenburg PJ, van Putten WL, Luten M, Oudejans J, et al. Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. *Ann Oncol.* 2011;22(**7**):1595-1600.
35. Gallamini A, Zaja F, Patti C, Billio A, Specchia MR, Tucci A, et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. *Blood.* 2007;110(**7**):2316-2323.
36. Ganjoo K, Hong F, Horning SJ, Gascoyne RD Natkunam Y, Swinnen LJ, et al. Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). *Leuk Lymphoma.* 2014;55(**4**):768-772.
37. Wulf GG, Altmann B, Ziepert M, D'Amore F, Held G, Greil R, et al. Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial. *Leukemia.* 2020; 35(**1**)143-155.
38. Bachy E, Camus V, Thieblemont C, Casasnovas R-O, Ysebaert L, Damaj G, Let al. Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma. *Blood.* 2020;136(**Supp 1**):32-33.
39. Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD Jaffe ES MacLennan KA, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. *Blood.* 2011;117(**12**):3402-3408.
40. Zhang X-M, Li Y-X, Wang W-H, Jin J, Wang S-L, Liu Y-P, et al. Survival Advantage With the Addition of Radiation Therapy to Chemotherapy in Early Stage Peripheral T-Cell Lymphoma, Not Otherwise Specified. *Int J Radiat Oncol Biol Phys..* 2012;85.
41. Rodríguez-López JL, Patel AK, Balasubramani GK, Glaser SM, Beriwal S, Vargo JA. Treatment selection and survival outcomes in Early-Stage peripheral T-Cell lymphomas: does anaplastic lymphoma kinase mutation impact the benefit of consolidative radiotherapy? *Leuk Lymphoma.* 2021;62(**3**):538-548.
42. Petrich AM, Helenowski IB, Bryan LJ, Rozell SA, Galamaga R, Nabhan C. Factors predicting survival in peripheral T-cell lymphoma in the USA: a population-based analysis of 8802 patients in the modern era. *Br J Haematol.* 2015;168(**5**):708-718.
43. Chen Z, Huang H, Li X, Fang X, Wang Z, Hong H, et al. Chemotherapy Plus Radiotherapy Versus Chemotherapy Alone for Patients With Peripheral T-Cell Lymphoma, Not Otherwise Specified. *Front Oncol.* 2021;11:607145-607145.
44. d'Amore F, Gaulard P, Trumper L, Corradini P, Kim WS, Specht L, et al. Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2015;26 (**Supp 5**):v108-115.
45. Yahalom J, Illidge T, Specht L, Hoppe RT, Li YX, Tsang R, et al. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. *Int J Radiat Oncol Biol Phys.* 2015;92(**1**):11-31.
46. Savage KJ, Ferreri AJ, Zinzani PL, Pileri SA. Peripheral T-cell lymphoma--not otherwise specified. *Crit Rev Oncol Hematol.* 2011;79(**3**):321-329.
47. Mikhaeel NG, Milgrom SA, Terezakis S, et al. The Optimal Use of Imaging in Radiation Therapy for Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group (ILROG). *Int J Radiat Oncol Biol Phys.* 2019;104(**3**):501-512.

48. Illidge T, Specht L, Yahalom J, Berthelsen AK, Hodgson D, Eich HT, et al. Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group. *Int J Radiat Oncol Biol Phys.* 2014;89(**1**):49-58.
49. Lowry L, Smith P, Qian W, Falk S, Benstead K, Illidge T, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: A randomised phase III trial. *Radiother and Oncol.* 2011;100(**1**):86-92.
50. Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. *Lancet.* 2019;393(**10168**):229-240.
51. Wulf GG, Altmann B, Ziepert M, D'Amore F, Held G, Greil R, et al. Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial. *Leukaemia.* 2021;35(**1**):143-155.
52. d'Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Upfront Autologuos Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01. *J Clin Oncol.* 2012.
53. Wilhelm M, Smetak M, Reimer P, Geissinger E, Ruediger T, Metzner B, et al. First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation. *Blood Cancer J.* 2016;6(**7**):e452-e452.
54. Park SI, Horwitz SM, Foss FM, Pinter-Brown LC, Carson KR, Rosen ST, et al. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. *Cancer.* 2019;125(**9**):1507-1517.
55. Fossard G, Broussais F, Coelho I, et al. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. *Ann Oncol.* 2018;29(**3**):715-723.
56. Advani R, Skrypets T, Cilallero M, Spinner MA, Manni M, Kim WS, et al. Outcomes and Prognostic Factors in Angioimmunoblastic T cell Lymphoma: Final Report from the International TCell Project. *Blood.* 2021 *(*Forthcoming)
57. Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Clemens MW, et al. NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021: Featured Updates to the NCCN Guidelines. *J Nat Comp Cancer Netw.* 2020;18(**11**):1460-1467.
58. d'Amore F, Gaulard P, Trümper L, Corradini P, Kim WS, Specht L, et al. Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2015;(**26**):v108-v115.
59. Kharfan-Dabaja MA, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C, et al. Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T cell and NK/T cell lymphomas: an international collaborative effort on behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant.* 2017;23(**11**):1826-1838.
60. Tournilhac O, Truemper L, Ziepert M, Bouabdallah K, Nickelsen M, Maury Set, al. First-Line Therapy Of T-Cell Lymphoma: Allogeneic Or Autologous Transplantation For Consolidation - Final Results Of The AATT Study. *Haematol Oncol.* 2019;37(**S2**):99-101.
61. Bellei M, Foss FM, Shustov AR, Horwitz SM, Marcheselli L, Kim WS, et al. The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. *Haematologica.* 2018;103(**7**):1191.
62. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. *Blood.* 2017;130(**25**):2709-2717.
63. Bartlett NL, Chen R, Fanale MA, et al. Retreatment with brentuximab vedotin in patients

with CD30-positive hematologic malignancies. *J Haematol Oncol.* 2014;7(**1**):1-8.
64. Shiota M, Fujimoto J, Semba T, Satoh H, Yamamoto T, Mori S. Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. *Oncogene.* 1994;9(**6**):1567-1574.
65. Gambacorti Passerini C, Farina F, Stasia A, Redaelli S, Ceccon M, Mologni L, et al. Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. *J Nat Cancer Inst.* 2014;106(**2**):378.
66. Skamene T, Crump M, Savage KJ, Reiman T, Kuruvilla J, Good D, et al. Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study(). *Leuk Lymphoma.* 2017;58(**10**):2319-2327.
67. Smith SM, Burns LJ, van Besien K, LeRademacher J, He W, Fenske TS, et al. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. *J Clin Oncol.* 2013;31(**25**):3100.
68. Stuver RN, Khan N, Schwartz M, et al. Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry. *Am J Haematol.* 2019;94(**6**):641-649.
69. Ma H, Cheng B, Falchi L, Acosta M, Federico M, Gisselbrecht C, et al. Survival benefit in patients with peripheral T-cell lymphomas after treatments with novel therapies and clinical trials. *Hematol Oncol.* 2020;38(**1**):51-58.
70. Shustov A, Pro B, Gisselbrecht C, Popplewell L, Bartlett NL, Lechowicz MJ, et al. Pralatrexate is effective as second-line treatment following cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) failure in patients with relapsed or refractory peripheral T-Cell lymphoma (PTCL). *Blood*.2010;116(**21**):4882 .
71. O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L ,Coiffier B, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. *J Clin Oncol.* 2011;29(**9**):1182.
72. Maruyama D, Nagai H, Maeda Y, Nakane T, Shimoyama T, Nakazato T, et al. Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma. *Cancer Sci.* 2017;108(**10**):2061-2068.
73. O'Connor OA, Amengual J, Colbourn D, Deng C, Sawas A. Pralatrexate: a comprehensive update on pharmacology, clinical activity and strategies to optimize use. *Leuk Lymphoma.* 2017;58(**11**):2548-2557.
74. Foss FM, Parker TL, Girardi M, Li A. Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate. *Leuk Lymphoma.* 2019;60(**12**):2927-2930.
75. Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O'Connor OA, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. *Blood.* 2014;123(**20**):3095-3100.
76. Foss F, Pro B, Prince MH, Sokol L, Caballero D, Horwitz S, et al. Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma. *Cancer Med.* 2017;6(**1**):36-44.
77. Gregory GP, Dickinson M, Yannakou CK, Wong J, Blombery P, Corboy G, et al. Rapid and durable complete remission of refractory AITL with azacitidine treatment in absence of TET2 mutation or concurrent MDS. *Hemasphere.* 2019;3(**2**)e187.
78. Lemonnier F, Dupuis J, Sujobert P, Tournillhac O, Cheminant M, Sarkozy C, et al. Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell

lymphoma. *Blood.* 2018;132(**21**):2305-2309.
79. Amengual JE, Lichtenstein R, Lue J, Sawas A, Deng C, Lichtenstein E, et al. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. *Blood.* 2018;131(**4**):397-407.
80. O'Connor OA, Falchi L, Lue JK, Marchi E, Kinahan C, Sawas A, et al. Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study. *Blood.* 2019;134(**17**):1395-1405.
81. Advani R, Horwitz S, Zelenetz A, Horning SJ. Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine. *Leuk Lymphoma.* 2007;48(**3**):521-525.
82. Kim W, Song S-Y, Ahn Y, Baek CH, Kim D, et al. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma? *Ann Oncol.* 2001;12(**3**):349-352.
83. Qi S-N, Yang Y, Song Y-Q, Wang Y, He X, Hu C, et al. First-line non–anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG. *Blood Adv.* 2020;4(**13**):3141-3153.
84. Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, et al. Concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: an updated analysis of the Japan clinical oncology group study JCOG0211. *J Clin Oncol.* 2012;30(**32**):4044-4046.
85. Jiang M, Zhang H, Jiang Y, Yang Q, Xie L, Liu W, et al. Phase 2 trial of "sandwich" L-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma. *Cancer.* 2012;118(**13**):3294-3301.
86. Kwong Y-L, Kim WS, Lim ST, Yang Q, Xie L, Liu W, et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. *Blood.* 2012;120(**15**):2973-2980.
87. Kwong Y, Kim S, Tse E, Oh S, Kwak J, Eom H, et al. Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma. *Ann Oncol.* 2018;29(**1**):256-263.
88. Wang X, Zhang L, Liu X, et al. Efficacy and survival in newly diagnosed advanced extranodal natural killer/T-cell lymphoma: a randomized, controlled, multicenter and open-labled study with Ddgp regimen versus SMILE regimen. *Blood*. 2019;134(Supp 1):463
89. Ghione P, Qi S, Imber BS, Seshan V, Moskowitz A, Galasso N et al. Modified SMILE (mSMILE) and intensity-modulated radiotherapy (IMRT) for extranodal NK-T lymphoma nasal type in a single-center population. *Leuk Lymphoma.* 2020;61(**14**):3331-3341.
90. Kanate AS, DiGilio A, Ahn KW, et al. Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis. *Brit J Haematol.* 2018;182(**6**):916-920.
91. Zhou Z, Li X, Chen C, Al Malki M, Jacobsen E, Steinberg A, et al. Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients. *Ann Haematol.* 2014;93(**11**):1889-1894.
92. Jaccard A, Gachard N, Marin B, Rogez S, Audrain M, Suarez F, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. *Blood.* 2011;117(**6**):1834-1839.
93. Li X, Cheng Y, Zhang M, Yan J, Li L, Fu X, et al. Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. *J Haematol Oncol.* 2018;11(**1**):1-8.

94. Kwong Y-L, Chan TS, Tan D, Kim S, J Poon LM, Mow B, et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. *Blood.* 2017;129(**17**):2437-2442.
95. Sieniawski M, Angamuthu N, Boyd K, Chasty R, Davies J, Forsyth P, et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. *Blood.* 2010;115(**18**):3664-3670.
96. Wöhrer S, Chott A, Drach J, Püspök A, Hejna M, Hoffmann M et al. Chemotherapy with cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone (CHOEP) is not effective in patients with enteropathy-type intestinal T-cell lymphoma. *Ann Oncol.* 2004;15(**11**):1680-1683.
97. Egan LJ, Walsh SV, Stevens FM, Connolly CE, Egan EL, McCarthy CF. Celiac-associated lymphoma. A single institution experience of 30 cases in the combination chemotherapy era. *J Clin Gastroenterol.* 1995;21(**2**):123-129.
98. Novakonic BJ, Novakonic S, Frkovic-Grazio S. A single-center report on clinical features and treatment response in patients with intestinal T cell non-Hodgkin's lymphomas. *Oncol Rep.* 2006;16(**1**):191-195.
99. Gale J, Simmonds PD, Mead GM, Sweetenham JW, Wright DH. Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. *J Clin Oncol.* 2000;18(**4**):795-795.
100. Casulo C, Schöder H, Feeney J, et al. 18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma. *Leuk Lymphoma.* 2013;54(**10**):2163-2167.
101. Wu H-B, Wang Q-S, Wang M-F, Lim R, Maragulia J, Zelenetz AD, et al. Utility of 18F-FDG PET/CT for staging NK/T-cell lymphomas. *Nuc Med Comm.* 2010;31(**3**):195-200.
102. Khong PL, Pang CB, Liang R, Kwong YL, Au WY. Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies. *Ann Haematol.* 2008;87(**8**):613-621.
103. Zhou X, Lu K, Geng L, Li X, Jiang Y, Wang X. Utility of PET/CT in the diagnosis and staging of extranodal natural killer/T-cell lymphoma: a systematic review and meta-analysis. *Medicine.* 2014;93(**28**).
104. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. *J Clin Oncol.* 2014;32(**27**):3059.



Figure 1. Algorithm for first-line treatment of PTCLs by subtype

*Consolidative radiotherapy can be considered for patients presenting with stage I/II disease. **Brentuximab-vedotin (BV) + CHP is recommended for ALCL.

PTCL NOS – peripheral T cell lymphoma not otherwise specified; AITL – angioimmunoblastic T cell lymphoma; ALCL – anaplastic large cell lymphoma; NKTCL – natural killer T cell lymphoma; CHOP – cyclophosphamide, doxorubicin, vincristine, prednisolone; CHOEP – cyclophosphamide, doxorubicin, vincristine, etoposide, prednisolone; CR – complete remission; ASCT – autologous stem cell transplantation; ALK+ ALCL – anaplastic lymphoma kinase-positive anaplastic large cell lymphoma; RT – radiotherapy; SMILE – dexamethasone, methotrexate, ifosfamide, L-asparaginase, etoposide; DGP – dexamethasone, asparaginase, gemcitabine, cisplatin.



Figure 2. Algorithm for treatment of PTCLs by subtype in the relapsed/refractory setting

*Patients not deemed eligible for these treatments can be considered for palliative options including radiotherapy, cyclosporin, prednisolone or best supportive care. **If available, options include pralatrexate, romidepsin or BV. PTCL NOS – peripheral T cell lymphoma not otherwise specified; AITL – angioimmunoblastic T cell lymphoma; ALCL – anaplastic large cell lymphoma; NKTCL – natural killer T cell lymphoma; EATL – enteropathy-associated T cell lymphoma; CR – complete remission; PR – partial remission; BV – brentuximab vedotin; ASCT – autologous stem cell transplantation; Allo – allogeneic stem cell transplantation; SMILE – dexamethasone, methotrexate, ifosfamide, L-asparaginase, etoposide; DGP – dexamethasone, asparaginase, gemcitabine, cisplatin.

ABSTRACT

Peripheral T-cell lymphomas (PTCLs) represent a heterogeneous disease group accounting for 10% of non-Hodgkin lymphomas. PTCL patients have typically poorer outcomes compared to aggressive B-cell lymphomas. However, such outcomes are heavily dependent upon subtype. Although anthracycline-based regimens such as cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) remain the standard first-line treatment for most aggressive PTCLs, there are important variations including incorporation of novel agents, use of radiotherapy and judicious consideration of stem cell transplantation. Relapsed or refractory disease represents a significant area of unmet need where chemotherapy intensification has limited efficacy and novel agents such as brentuximab vedotin and pralatrexate provide additional opportunities for attainment of remission and potential stem cell transplant. In the future, pre-therapy prognostic biomarkers including genomic characterisation, may aid in risk stratification and help guide initial patient management to improve survival. There is an urgent need to better understand the pathogenesis of PTCLs to facilitate novel drug combinatorial approaches to improve survival. This position statement represents an evidence-based synthesis of the literature for application in Australian and New Zealand practice.

KEYWORDS

Peripheral T-cell Lymphoma, PTCL, AITL, ALCL, chemotherapy.

TABLE 1: Levels of Evidence

*Adapted from NHMRC Evidence Hierarchy Table 2009

Level	Body of Evidence
I	A systematic review of level II studies
II	A randomised controlled trial
III-1	A trial with an independent blinded comparison with a valid reference standard
III-2	A comparative study with concurrent controls e.g. nonrandomised trial, cohort or case control study
III-3	A comparative study without concurrent controls, e.g. historical control study, or 2 or more single arm study
IV	Case series with post-test outcomes

IMJ_15595_Table 1.JPG

TABLE 2: Grades of recommendations

Grade of Recommendation	Description
A	Body of evidence can be trusted to guide clinical practice
B	Body of evidence can be trusted to guide clinical practice in most situations
C	Body of evidence provides some support for recommendation(s), but care should be taken in its application
D	Body of evidence is weak, and recommendation must be applied with caution

IMJ_15595_Table 2.JPG

Diagnosis, management and follow up of peripheral T cell lymphomas: A Consensus Practice Statement from the Australasian Lymphoma Alliance

Hapgood.G[1,2], Latimer. M[3], Lee. S.T[4,5], Kuss. B[6,7], Lade. S[8], Tobin. J.W.D[9,10], Purtill. D[11,12], Campbell. B.A[5,8], Prince. H.M[5,8], Hawkes. E.A[4,5], Shortt. J[13,14], Radeski. D[11,15]

Corresponding Author: Greg Hapgood

Dept Haematology, Princess Alexandra Hospital, 199 Ipswich Rd, Woolloongabba QLD 4102, Australia

Email: Greg.Hapgood@health.qld.gov.au

Author Details & Affiliations

Greg Hapgood, Haematologist,
[1] Princess Alexandra Hospital, Brisbane, Australia
[2]University of Queensland, Brisbane, Australia
Maya Latimer, Haematologist,
[3] The Canberra Hospital, Canberra, Australia
Sze Ting Lee, Nuclear Medicine Physician
[4]Olivia Newton John Cancer Research Institute, Austin Health, Melbourne, Australia
[5]University of Melbourne, Melbourne, Victoria, Australia
Bryone Kuss, Haematologist
[6]Flinders University, Bedford Park, Australia
[7]Flinders Medical Centre, Bedford Park, Australia
Stephen Lade, Anatomical Pathologist
[8]Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Joshua W.D. Tobin, Haematology advanced trainee
[9]Mater Health, South Brisbane, Australia
[10]Mater Research Institute, University of Queensland, Brisbane, Australia
Duncan Purtill, Haematologist,
[11]University of Western Australia, Perth, Australia
[12]Fiona Stanley Hospital, Perth, Australia
Belinda A. Campbell, Radiation Oncologist
[5]University of Melbourne, Melbourne, Victoria, Australia
[8]Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
H.Miles Prince, Haematologist
[5]University of Melbourne, Melbourne, Victoria, Australia
[8]Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Eliza A Hawkes, Medical Oncologist
[4]Olivia Newton John Cancer Research Institute, Austin Health, Melbourne, Australia
[5]University of Melbourne, Melbourne, Victoria, Australia
[13]Monash University, Clayton, Australia
Jake Shortt, Haematologist
[13]Monash University, Clayton, Australia
[14]Monash Health, Clayton, Australia
Dejan Radeski, Haematologist
[15]Sir Charles Gairdner Hospital, Nedlands, Australia.

Author Contributions

GH: coordinated the project, drafted, revised, critically reviewed and edited the work.

DR: drafted, revised and critically reviewed the work.

ML, STL, BK, SL, JT, DP, BC, MP, EH, JS: drafted and reviewed the work.

All authors contributed to the design of the work, approved the final version and are accountable for all aspects of the work

Conflict of Interest

JT: Honorarium – Roche.

MP: Advisory boards – Takeda, BMS-Celgene, Allergan. Research Grant – Allergan.

EH: Advisory board - Merck Sharpe & Dome, Gilead, Roche, Antigene, Astra Zeneca, Bristol Myers Squibb, Janssen. Research Grants - Bristol Myers Squibb, Merck KgA, Astra Zeneca and Roche, Speaker's bureau - Janssen, Roche.

JS: Advisory board – Astellas, BMS/Celgene. Research funding – Amgen, Astex, BMS/Celgene. Speaker's bureau – Takeda.

GH: Advisory board – Takeda.

Word count

Abstract- 170
Main Document: 3802